OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares plunged more than 48% pre-market after the company said results from its Phase 3 SYNERGY trial to add custirsen to standard first-line treatment of docetaxel/prednisone in men with metastatic prostate cancer failed to meet primary endpoints. The stock which was halted from trading ahead of the news, recently changed hands…
Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) and Acasti Pharma Inc (NASDAQ:ACST), a Neptune subsidiary, Sunday night announced that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec Ltd. and Enzymotec Ltd(NASDAQ:ENZY) that resolves the International Trade Commission’s investigation of infringement of Neptune’s composition of matter patents, related federal court actions initiated by…
The American Despositary Receipts of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) edged up in recent pre-market trading on Monday after announcing over the weekend an agreement it has signed with Takeda Pharmaceutical for the marketing and sale of Rasagiline in Japan. Rasagiline is a treatment for Parkinson’s Disease developed by TEVA and has been approved in…
Shares of AstraZeneca plc (ADR)(NYSE:AZN) reached a new high in pre-market trading as Pfizer Inc.(NYSE:PFE) confirmed it has attempted to renew negotiations on a possible merger. Pfizer submitted a preliminary indication of interest to the board of directors of AstraZeneca in January 2014 regarding the possible merger. AstraZeneca declined to pursue negotiations at that time, but…
On Monday morning, it was announced that Avago Technologies (AVGO), a leader in advanced optical, analog and mixed-signal chip design, will acquire LSI Corp (LSI), a strong market participant in hard disk drive semiconductor, system-level silicon for communications and server applications and flash storage solutions. AVGO will pay $6.6 billion for LSI, or $11.15 per…
ARM Holdings reported 3Q13 results on Thursday that were above consensus estimates. On a positive note, ARMH’s license revenue continues to significantly exceed expectations, and ARM PD (Processor Division) royalty revenue continues to outperform ARM’s served available market (SAM) according to management’s guidance. Admittedly, shares are richly valued, and the market clearly wanted a perfect…
